Netherlands· NL-91811fb09c80
Raxone 150 mg filmomhulde tabletten
A idebenone product containing idebenon, registered in Netherlands by Chiesi Farmaceutici S.p.A.. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Idebenone is registered in 12 of 19 countries.
Countries holding a registration under ATC N06BX13 (idebenone), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Idebenone · ATC N06BX13
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of idebenone costs, country by country.
Normalised to the WHO defined daily dose (0.9 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Idebenone · price per daily dose (0.9 g)
USD · FX 28 Sept 2026
- IT Italy$395.68
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- IDEBENON
- Manufacturer
- Chiesi Farmaceutici S.p.A.
- Country
- Netherlands (NL)
- ATC code
- N06BX13
- ATC class
- Idebenone
- Defined daily dose
- 0.9 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/15/1020
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idebenone in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandRaxoneOrifarm Oy
- CzechiaRAXONEChiesi Farmaceutici S.p.A., Parma
- SpainRAXONE 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULAChiesi Farmaceutici S.P.A.
- FranceRAXONE 150 mg, comprimé pelliculéCHIESI FARMACEUTICI
- IrelandRaxone 150 mg film-coated tabletsChiesi Farmaceutici S.p.A.
- IcelandRaxoneChiesi Farmaceutici S.p.A.*
- NorwayRaxoneChiesi Farmaceutici S.p.a.
- PolandRaxoneChiesi Farmaceutici S.p.A.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Iceland · Raxone
- Liechtenstein · Raxone
- Norway · Raxone
- Portugal · Amizal, Cerestabon
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/47d2586c-e472-4eba-b32d-928731ddc4d3 GET /v1/drugs/47d2586c-e472-4eba-b32d-928731ddc4d3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/raxone-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Idebenone",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp115566",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"LACTOSE 1-WATER",
"MACROGOL 3350",
"MAGNESIUMSTEARAAT (E 470b)",
"POLYVINYLALCOHOL (E 1203)",
"POVIDON K 25 (E 1201)",
"SILICIUMDIOXIDE (E 551)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)",
"ZONNEGEEL FCF ALUMINIUMLAK (E 110)"
],
"substances": [
"IDEBENON"
],
"leaflet_url": null,
"authorised_at": "2015/09/08",
"procedure_number": "EMEA/H/C/003834",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/15/1020",
"additional_monitoring": "N"
}See everything about idebenone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.